AXON vs HALO

Key Takeaways

• Axon Enterprise and Halozyme Therapeutics operate in fundamentally different industries — public safety technology versus biopharmaceutical drug delivery — yet both have delivered strong double-digit revenue growth in recent quarters.
• AXON shares have experienced significant volatility, trading roughly 43% below their 52-week high as of recent weeks, pressured by valuation concerns, high stock-based compensation, and an earnings miss despite robust top-line momentum.
• HALO has been a steadier performer year-to-date, up more than 20% in 2026, supported by record royalty revenue, a capital-light business model, and sharply raised forward guidance that calls for nearly 90% to 99% non-GAAP EPS (earnings per share) growth.
• Valuation profiles diverge sharply: AXON trades at a forward P/E (price-to-earnings ratio) above 60, while HALO carries a forward P/E near 11, making the risk-reward calculus distinctly different for each name.
• Both companies are pursuing acquisitive growth strategies — AXON with its Carbyne deal to build a next-generation 911 platform, and HALO with the Elektrofi and Surf Bio acquisitions to extend its drug delivery technology portfolio into the 2040s.
• Sentiment around AXON has been mixed following recent earnings disappointment, while HALO has benefited from consistent guidance raises and an expanding roster of pharmaceutical partners.

Introduction

Investors scanning the market for growth-oriented names may encounter two very different companies that nonetheless share compelling expansion narratives: AXON, the dominant force in public safety technology known for TASER devices and cloud-based law enforcement software, and HALO, a biopharmaceutical innovator whose ENHANZE drug delivery technology underpins multiple blockbuster therapies. This stock comparison is relevant for traders and investors evaluating how growth stories in distinct sectors — industrials-adjacent technology versus biotechnology royalties — stack up against each other in terms of momentum, valuation, and risk. Understanding the contrasts between these two names can help clarify which profile aligns with different investment objectives in the current market environment.

AXON Overview and Recent Performance

AXON (Axon Enterprise, Inc.) is a technology leader serving global public safety, providing TASER conducted energy devices, body-worn and in-car cameras, drones, and an expanding suite of cloud software solutions including digital evidence management, AI-powered productivity tools such as Draft One, and real-time operations platforms. The company has posted an impressive streak of consecutive quarters with revenue growth above 30%, closing full-year 2025 with approximately $2.74 billion in revenue, representing roughly 31% annual growth. Annual Recurring Revenue (ARR) — a metric reflecting contracted, subscription-based income — reached $1.3 billion, growing 41% year-over-year.

Despite this operational momentum, AXON shares have faced considerable headwinds in recent months. The stock remains roughly 43% below its all-time closing high reached in August 2025. A confluence of factors has weighed on sentiment: elevated stock-based compensation expenses that approached $610 million in 2025, a forward P/E ratio that places the stock at a premium to most industrial peers, and a Q3 2026 earnings miss where EPS of $1.17 fell notably short of consensus estimates. In recent weeks, however, the stock experienced a sharp rally following disclosures of high-profile investor interest and a sizeable federal TASER contract solicitation from Immigration and Customs Enforcement (ICE), demonstrating the stock's sensitivity to catalyst-driven moves. Revenue growth from AI-powered products surged over 700% year-over-year, underscoring the innovation runway ahead, even as profitability metrics remain under scrutiny.

HALO Overview and Recent Performance

HALO (Halozyme Therapeutics, Inc.) is a biopharmaceutical company that pioneered the ENHANZE drug delivery technology, which uses its proprietary enzyme rHuPH20 to enable subcutaneous (under-the-skin) administration of injected drugs — reducing treatment burden and improving patient convenience. The company operates a royalty-driven business model: it licenses ENHANZE to major pharmaceutical partners including Roche, Johnson & Johnson, Pfizer, Bristol-Myers Squibb, and argenx, and collects royalties on global sales of ENHANZE-enabled products. Ten such products are now commercialized, with three blockbusters — DARZALEX SC, Phesgo, and VYVGART Hytrulo — driving the bulk of royalty revenue.

Full-year 2025 results underscored the strength of this model: total revenue reached a record $1.397 billion, up 38% year-over-year, while royalty revenue surged 52% to $868 million. HALO shares have climbed more than 20% year-to-date in 2026 and approximately 39% over the trailing twelve months, recently trading near the upper end of their 52-week range. Management raised 2026 guidance substantially, projecting total revenue of $1.71 billion to $1.81 billion and non-GAAP diluted EPS of $7.75 to $8.25 — representing nearly double year-over-year earnings growth at the midpoint. Key catalysts include the strategic acquisitions of Elektrofi's Hypercon microparticle technology and Surf Bio's hyperconcentration technology, both of which extend Halozyme's royalty opportunity horizon into the mid-2040s. A patent infringement lawsuit against Merck related to subcutaneous Keytruda adds a layer of legal uncertainty, but the core royalty stream continues to demonstrate remarkable durability.

Trending AI Robots

Navigating stock selection in a dynamic market can be challenging, which is why many traders now turn to algorithmic tools for data-driven insights. Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots designed to identify opportunities across thousands of tickers in real time. With hundreds of AI trading bots available on the platform — each employing distinct strategies, timeframes, and risk parameters — only those demonstrating the strongest alignment with current market conditions earn a place in this featured section. The bots shown on this page span multiple trading styles, from swing trading and trend following to mean-reversion and breakout strategies, with statistical track records that traders can review. Whether you are looking for bots that specialize in individual stocks like those discussed in this article or diversified baskets, the Trending AI Robots page offers a practical starting point for exploring systematic, technology-driven approaches to market participation.

Head-to-Head Comparison

The most immediate contrast between AXON and HALO lies in their business models. Axon is a hardware-plus-software ecosystem company that sells TASER devices and body cameras, often paired with multi-year subscription plans that generate recurring revenue. Halozyme, by contrast, is an intellectual property and royalty company: its ENHANZE technology is embedded in partner products, and it collects a percentage of global sales with minimal incremental capital expenditure. This structural difference translates into vastly different margin profiles — Halozyme's operating margin runs near 49% with a profit margin of roughly 23%, while Axon's profit margin is in the single digits as the company reinvests heavily in R&D and sales expansion.

Growth trajectories also diverge in important ways. Axon's revenue base is larger at roughly $2.8 billion, growing at about 30% annually, supported by new product categories such as drones, counter-drone systems, and AI software. Halozyme's smaller revenue base of approximately $1.4 billion is growing faster at the royalty level — royalty revenue growth of 52% in 2025 — and the company has guided for 87% to 99% non-GAAP EPS growth in 2026. In terms of risk, Axon faces questions about whether its premium valuation can be sustained if earnings execution continues to lag revenue growth, along with sensitivity to government budget cycles. Halozyme's risks center on partner product trajectories — if any of the three blockbuster therapies experience competitive pressure, the royalty stream could be impacted — as well as its ongoing patent litigation.

Sector exposure further differentiates the two. Axon is tied to public safety spending, law enforcement technology, and increasingly enterprise security, making it sensitive to government procurement trends and social policy dynamics. Halozyme is exposed to the pharmaceutical and biotechnology cycle, where regulatory approvals, drug pricing debates, and clinical trial outcomes drive sentiment. From a market sentiment standpoint, Halozyme has maintained steadier upward momentum with less drawdown from highs, while Axon has exhibited higher beta (a measure of volatility relative to the broader market) and more dramatic price swings — including a recent seven-day rally that added roughly 44% in a single burst.

Tickeron AI Verdict

Based on the observable data, Tickeron's AI would likely tilt in favor of HALO under current market conditions, though with appropriate probabilistic caution. Several factors support this assessment: Halozyme's trend has been more consistent and less volatile, with the stock trading near 52-week highs and supported by a steady cadence of upward guidance revisions. The royalty-driven business model offers superior operating margins and more predictable cash flow generation, while the forward P/E ratio near 11 suggests a valuation that has not yet fully priced in the near-doubling of earnings projected for 2026. Axon, while carrying undeniable long-term potential given its AI product pipeline and dominant market position, faces a more uncertain near-term path: its elevated valuation multiple, recent earnings miss, and high stock-based compensation introduce variables that an AI model prioritizing trend stability and risk-adjusted momentum would likely weigh against it. That said, should Axon demonstrate consecutive quarters of earnings recovery and sustained margin expansion, the relative attractiveness of the two names could shift quickly.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations